PROTEOMICS ALLIANCE FOR CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Proteomics Alliance for Cancer (PAC) is supported by the Michigan Life Sciences Corridor (MLSC)/Michigan Economic Development Corporation, and affiliated with the UM NCRR Center The Proteomics Alliance for Cancer has brought together key laboratories in the cancer proteomics domain at the University of Michigan, Van Andel Research Institute, local firms, MLSC Core Technology Alliance, and the UM NCRR Center. The PAC has demonstrated the usefulness for clinical studies of the Cy3/Cy5 double-labeling of paired clinical specimens (before and after treatment, or before and after development of complications), combined with our 3-dimensional fractionation and mass spec analysis scheme. Novel findings were obtained for graft-versus-host disease after bone marrow transplantation, a treatment for certain kinds of cancers. PAC served as the beta-site for the new Beckman-Coulter PF 2D proteomics equipment and as one of several beta-sites for the new Agilent immuno-affinity column for depletion of the six most abundant proteins in plasma/serum. We made major contributions to the improvements of these new products and have had the benefit of early use of the equipment. Both companies have introduced these products commercially. We concluded that depletion of albumin and several other highly abundant proteins in plasma can markedly improve the resolution and sensitivity of detection of less abundant proteins, including those which may be derived from organs and tissues that are sites of origin of disease processes. We are pursuing the challenging aim of enhancing throughput in liquid-based separation systems. At the same time, we are utilizing the existing LC systems to create 2000 fractions from tumor cell lysates for protein microarrays both at VAI and UM that have promise for diagnostic applications. Substantial progress has been made collaboratively in the Haab lab at Van Andel and the Hanash lab at UM on prostate and lung cancer cell protein microarrays for detection of circulating auto-antibodies against these proteins in the sera of patients with prostate cancer or lung cancer, respectively. These studies have major potential to identify and validate useful biomarkers for earlier diagnosis of these and other cancers.